Costly medicines are a burden for both individual patients and national budgets. The Prescription Drug Law within the Inflation Reduction Act (IRA) exemplifies efforts to make medicines more affordable. The production of biologics requires intricate manufacturing processes within a highly regulated environment, leading to high production expenses. Greater control over the production costs of biologics has emerged as a pivotal factor for drug manufacturers to uphold competitiveness in the biopharmaceutical industry. Taking monoclonal antibody products as an example, this webinar focuses on reducing the commercial production costs of biopharmaceuticals.